EPA declares TCE a human carcinogen and initiates cleanups

This past week, the Environmental Protection Agency released its final health risk assessment regarding the widely used industrial solvent trichloroethylene (TCE), declaring it far more dangerous to humans than previously believed, causing various health problems including cancers of the liver and kidney, as well as lymphoma.

In EPA terminology, the final assessment "characterizes [TCE] as carcinogenic to humans and as a human noncancer health hazard."

The new risk assessment means that the federal drinking-water standard for TCE will be reevaluated, and will likely result in several new clean-up strategies in places ranging from the nation's aquifers to the several hundred Superfund sites.

That this risk assessment—which was first drafted in 2001—ever saw the light of day is surprising, considering the amount of resistance the EPA met in the form of other federal government agencies, including the US Department of Defense, the US Department of Energy, NASA, and officials at the Pentagon. Resistance typically came in the form of insistence on 'more convincing proof' that TCE was causing cancer.

The EPA risk assessment will lend credibility to those people who believe their cancer was caused by TCE pollution and have initiated litigation against corporate polluters.

TCE exposure can occur by bathing in contaminated water, breathing air by contaminated vapors, and the toxic compound has been found in every state in the Union.

Source

EPA News

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap